Ambry Genetics has launched four targeted sequencing-based cancer panels: CancerNext, BreastNext, ColoNext, and OvaNext.
The CancerNext panel targets and sequences 23 genes that contribute to increased risk for breast, colon, ovarian, uterine, and other cancers. It excludes the BRCA1 and BRCA2 genes. The test sequences the coding regions of all 23 genes, plus at least 20 bases into the 5' and 3' ends of the introns. Gross deletions and duplications are analyzed for 19 of the genes.
BreastNext, ColoNext, and OvaNext analyze 14, 15, and 20 genes that are specific to breast, colon, and ovarian cancer risk, respectively. Turnaround time is between 70 and 84 days.